Medicinal product with the active substance Bimekizumab (ATC: L04AC21)
Arzneimittel mit dem Wirkstoff Bimekizumab (ATC: L04AC21)
Germany · Magdeburg · how to bid here →
Your path to submission
- Deadline: 30 October at 22:00 — 24 days left.
- You submit on Vergabemarktplatz (cosinex) — not here and not by e-mail. ↗ Free bidder account on the cosinex platform required (created instantly); offers go through the bidding tool, usually plain text form suffices — no qualified signature. Sort out account and signature first — not on submission day.
- Offer and evidence in: DEU.
- Collect your evidence — use the eligibility analysis above: it lists the requirements and, for known certificates, how to get them.
Clement What the numbers say about this buyer
- In this sector the buyer awards roughly every 4 months (36 awards, most recently September 2026) — the next award is due around January 2027 by that rhythm. The last award went to Novo Nordisk Pharma GmbH.n = 36
- 49% of this buyer's awards went to companies that had already won here before (103 awards since 2018, spread over 53 companies). That is well below the sector norm (62%) — this buyer switches suppliers more often than others.n = 103 awards since 2018
- The median procedure drew just one bid (99 procedures with a bid count); 60% ended with a single bidder. Sector: median 2 bids.n = 99
- Across 119 procedures with structured selection criteria, this buyer most often required: Trade register enrolment (118 of 119), Quality management (2 of 119), References: services (2 of 119), Professional liability insurance (2 of 119).n = 119
- Not one of the 103 awards with a known winner country has gone to a foreign company so far. Sector average: 1%.n = 103
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.
Foreign bidders
In Germany · Medical equipment & pharma, 265 contracts went to foreign companies over the last 3 years (of 22,200 recorded awards) — mostly from Austria, Netherlands, France.
Typical field: median 1 (from 106 awards).
What the buyer is looking for
Conclusion of non-exclusive discount agreements pursuant to § 130c(1) SGB V in conjunction with § 130a(9) SGB V for finished medicinal products containing the active substance bimekizumab (ATC: L04AC21) at any time in the context of a so-called "open-house model". A contract is concluded with each pharmaceutical company that meets the requirements for participation. There is no exclusivity. Accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The earliest contract start date is 01.01.2025. On this basis, the maximum duration of the contract is 24 months. The contract ends on 31.12.2026 regardless of the beginning of the contract. Should AOK Sachsen-Anhalt tender exclusive contracts for the active substances during the term of the contract in accordance with the relevant procurement law…
Show full description
… provisions, the contracts concluded within the framework of this publication will be terminated in accordance with the contractual provisions. This publication does not constitute the award of a public contract within the meaning of § 103 GWB or public procurement law. Publication in the Supplement to the Official Journal of the European Union shall be carried out in order to ensure as much transparency as possible as regards the intended conclusion of contracts.
What you must prove — eligibility criteria
From the notice of the same procedure on TED — Tenders Electronic Daily.
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Novartis Pharma GmbH · Nürnberg | 7 | 2013–2026 |
| PIK AG | 5 | 2025 |
| Bayer Vital GmbH · Leverkusen | 5 | 2014–2026 |
| GlaxoSmithKline GmbH & Co. KG · München | 5 | 2012–2026 |
| Pfizer Pharma GmbH · Berlin | 5 | 2023–2026 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.
How to bid
Guide: how to apply on cosinex Vergabemarktplatz / DTVP → Registration, signature, fees — from the operator's bidder manual.